Nutriband Inc. (NASDAQ:NTRB) Short Interest Update

Nutriband Inc. (NASDAQ:NTRB) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 361,000 shares, an increase of 37.7% from the January 31st total of 262,100 shares. Approximately 7.1% of the shares of the company are short sold. Based on an average daily volume of 202,200 shares, the days-to-cover ratio is presently 1.8 days.

Nutriband Price Performance

NASDAQ NTRB traded down $0.39 during trading on Monday, reaching $6.88. The company’s stock had a trading volume of 50,698 shares, compared to its average volume of 310,160. The stock has a market capitalization of $76.41 million, a PE ratio of -9.69 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.96 and a quick ratio of 4.83. The firm has a fifty day moving average of $6.16 and a 200 day moving average of $5.61. Nutriband has a one year low of $2.22 and a one year high of $11.78.

Nutriband (NASDAQ:NTRB) last announced its earnings results on Tuesday, December 3rd. The company reported ($0.12) earnings per share for the quarter. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%. Analysts expect that Nutriband will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Haven Private LLC acquired a new stake in shares of Nutriband Inc. (NASDAQ:NTRB) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 11,561 shares of the company’s stock, valued at approximately $54,000. Haven Private LLC owned about 0.10% of Nutriband at the end of the most recent quarter. 19.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Noble Financial initiated coverage on Nutriband in a research note on Wednesday, January 22nd. They issued an “outperform” rating and a $13.00 target price on the stock.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.